Diferencia entre revisiones de «HIV post-exposure prophylaxis»

Sin resumen de edición
Línea 18: Línea 18:
*Common side-effects = constitutional, gastrointestinal
*Common side-effects = constitutional, gastrointestinal


===Specific Regimens (CDC)===
=== Specific Regimens (CDC) ===
#Basic
#Basic (2-Drug)
##Exposures for which there is a recognized transmission risk
##Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD
##4 week, 2 drug regimen (normally zidovudine and lamivudine)
##OR, Zidovudine-Lamivudine 300mg/150mg (Combivir): 1 tab PO BID
#Expanded
#Expanded (3-Drug)
##High risk exposures
##Ritonavir-Lopinavir (Kaletra)
 
##High risk exposures  
##Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir)
##Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir)



Revisión del 04:44 24 nov 2012

Workup

  1. Td
  2. Hepatitis B PEP for non-vaccinated
    1. Hepatitis B immunoglobulin and/or vaccine
  3. Source labs
    1. Rapid HIV, hep pannel, RPR?
  4. Exposed labs
    1. Rapid HIV, hep pannel, RPR?
  5. Consider HIV PEP
    1. CBC, C7, LFTs, Icon if considering HIV PEP

^Currently no PEP for Hep C

HIV PEP

  • ~79% transmission reduction
  • Initiate ASAP (goal = 1-2 hours)
  • >36 hours: normally deferred, unless particularly high risk
  • Common side-effects = constitutional, gastrointestinal

Specific Regimens (CDC)

  1. Basic (2-Drug)
    1. Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD
    2. OR, Zidovudine-Lamivudine 300mg/150mg (Combivir): 1 tab PO BID
  2. Expanded (3-Drug)
    1. Ritonavir-Lopinavir (Kaletra)
    1. High risk exposures
    2. Basic regimen + protease inhibitor (e.g. indinavir or nelfinavir)

High Risk

Source

  1. Symptomatic HIV/AIDS
  2. Acute seroconversion
  3. High viral load

Exposure

  1. Deep injuries
  2. Visible blood on device
  3. Injuries sustained placing a catheter in a vein/artery

See Also

Occupational Exposure

Source

8/07 DONALDSON